%PDF-1.4
%
79 0 obj
<>
endobj
76 0 obj
<>
endobj
162 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-01-05T11:57:53Z
2024-03-28T15:57:21-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T15:57:21-07:00
application/pdf
Heather
uuid:ebb825f9-1dd1-11b2-0a00-260927edca00
uuid:ebb825fb-1dd1-11b2-0a00-380000000000
endstream
endobj
65 0 obj
<>
endobj
66 0 obj
<>
endobj
80 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 51 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 53 0 R/Type/Page>>
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 55 0 R/Type/Page>>
endobj
31 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 57 0 R/Type/Page>>
endobj
34 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 59 0 R/Type/Page>>
endobj
193 0 obj
[197 0 R]
endobj
194 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 57 714.5293 Tm
[(10.)-875.1 (Stoll )17.7 (T)74 (, Gordon C, Seifert B, et al. Consistency and validity of)]TJ
2.175 -1.25 Td
(patient administered assessment of quality of life by the MOS )Tj
0 -1.25 TD
(SF-36: its association with disease activity and damage in patients)Tj
T*
(with systemic lupus erythematosus. J Rheumatol 1997;24:1608-14.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Dobkin PL, Da Costa D, Dritsa M, et al. Quality of life in systemic)]TJ
2.1381 -1.25 Td
(lupus erythematosus patients during more and less active disease)Tj
T*
[(states: Dif)17.7 (ferential contributors to mental and physical health.)]TJ
T*
(Arthritis Care Res 1999;12:401-10.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Hochber)17.7 (g MC. Updating the )54.8 (American College of Rheumatology)]TJ
2.175 -1.25 Td
(revised criteria for the classification of systemic lupus )Tj
T*
[(erythematosus [letter]. )54.8 (Arthritis Rheum 1997;9:1725.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Burckhardt CS, )54.8 (Archenholtz B, Bjelle )54.8 (A. Quality of life of women)]TJ
2.175 -1.25 Td
(with systemic lupus erythematosus: a comparison with women with)Tj
T*
(rheumatoid arthritis. J Rheumatol 1993;20:977-81.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Hochber)17.7 (g MC, Sutton JD. Physical disability and psychosocial)]TJ
2.175 -1.25 Td
(dysfunction in systemic lupus erythematosus. J Rheumatol)Tj
0 Tc 0 Tw T*
(1988;15:959-64.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Gladman DD, Urowitz MB. Systemic lupus erythematosus. Clinical)]TJ
2.175 -1.25 Td
[(and laboratory features. In: Klippel JH, )17.7 (W)79.9 (eyand CM, )17.7 (W)79.9 (ortmann)]TJ
T*
[(RL, editors. Primer on the rheumatic diseases. 1)36.8 (1th ed. )54.8 (Atlanta:)]TJ
T*
(Arthritis Foundation; 1997:251-7.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Friedman )54.8 (A)79.8 (W)91.8 (, )54.8 (Alarcon GS, McGwin G Jr)39.7 (, et al. Systemic lupus)]TJ
2.175 -1.25 Td
[(erythematosus in three ethnic groups. IV)128.8 (. Factors associated with)]TJ
T*
[(self-reported functional outcome in a lar)17.7 (ge cohort study)64.8 (. LUMINA)]TJ
T*
[(Study Group. )54.8 (Arthritis Care Res 1999;12:256-66.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Clarke )54.8 (AE, Bloch DA, Danof)17.7 (f DS, Esdaile JM. Decreasing costs)]TJ
2.175 -1.25 Td
(and improving outcomes in systemic lupus erythematosus: using)Tj
T*
[(regression trees to develop health policy)64.8 (. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1994;21:2246-53.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (T)35 (urk DC, Okifuji )54.8 (A, Sinclair JD, Starz )17.7 (TW)91.7 (. Pain, disability)64.8 (, and)]TJ
2.175 -1.25 Td
(physical functioning in subgroups of patients with fibromyalgia. )Tj
T*
(J Rheumatol 1996;23:1255-62.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Holm MB, Rogers JC, Kwoh CK. Predictors of functional disability)]TJ
2.175 -1.25 Td
[(in patients with rheumatoid arthritis. )54.8 (Arthritis Care Res)]TJ
0 Tc 0 Tw T*
[(1998;1)36.9 (1:346-55.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Roberts BL, Matecjyck MB, )54.8 (Anthony M. )17.7 (The ef)17.7 (fects of social)]TJ
2.175 -1.25 Td
(support on the relationship of functional limitations and pain to)Tj
T*
[(depression. )54.8 (Arthritis Care Res 1996;9:67-73.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Bollen KA. Structural equations with latent variables. New )36.8 (Y)99.8 (ork:)]TJ
2.175 -1.25 Td
[(W)39.8 (iley-Interscience; 1989.)]TJ
-2.55 -1.25 Td
[(21a.)-806.2 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
2.55 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH.)]TJ
2.175 -1.25 Td
[(Derivation of the SLEDAI. )54.8 (A)-220.1 (disease activity index for lupus)]TJ
T*
[(patients. )17.7 (The Committee on Prognosis Studies in SLE. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1992;35:630-40.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(23.)-875.1 (Liang MH, Socher SA, Larson MG, Schur PH. Reliability and)]TJ
2.175 -1.25 Td
(validity of six systems for the clinical assessment of disease)Tj
T*
[(activity in systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
[(1989;32:1)36.9 (107-18.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Abrahamowicz M, Fortin PR, du Ber)17.7 (ger R, Nayak )17.7 (V)128.9 (, Neville C,)]TJ
2.175 -1.25 Td
[(Liang MH. )17.7 (The relationship between disease activity and expert)]TJ
T*
[(physician\325)54.8 (s decision to start major treatment in active systemic)]TJ
T*
[(lupus erythematosus: )54.8 (A)-220.1 (decision aid for development of entry)]TJ
T*
(criteria for clinical trials. J Rheumatol 1998;25:277-84.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Liang MH, Socher SA, Roberts )17.7 (WN, Esdaile JM. Measurement of)]TJ
2.175 -1.25 Td
[(systemic lupus erythematosus activity in clinical research. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1988;31:817-25.)Tj
-0.00011 Tc 0.00729 Tw -2.175 -1.25 Td
[(26.)-875.1 (Kerns )-17.7 (RD, T)35 (urk )-17.8 (DC, )-17.8 (Rudy TE. The W)79.9 (est )-17.7 (Haven\320Y)99.8 (ale)]TJ
0.02499 Tw 2.175 -1.25 Td
(Multidimensional Pain Inventory \(WHYMPI\). Pain )Tj
0 Tc 0 Tw T*
(1985;23:345-56.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(27.)-875.1 (Meenan RF)79.7 (, Gertman PM, Mason JH. Measuring health status in)]TJ
2.175 -1.25 Td
[(arthritis: )17.7 (The )54.8 (Arthritis Impact Measurement Scales. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1980;23:146-52.)Tj
-0.00011 Tc 0.02499 Tw 30.825 80 Td
[(28.)-875.1 (Melzack R. )17.7 (The Short-Form McGill Pain Questionnaire. Pain)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1987;30:191-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(29.)-875.1 (Radlof)17.7 (f LS. )17.7 (The CES-D scale: )54.8 (A)-220.1 (self-report depression scale for)]TJ
2.175 -1.25 Td
[(research in the general population. )54.8 (Appl Psychol Meas )]TJ
0 Tc 0 Tw T*
(1977;1:385-401.)Tj
0.0249 Tw -2.175 -1.25 Td
[(30.)-875 (L)55.1 (yness JM, Noel )17.7 (TK, Cox C, King DA, Conwell )36.8 (Y)129 (,)0.1 ( Caine ED.)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(Screening for depression in elderly primary care patients. )54.8 (A)]TJ
T*
(comparison of the Center for Epidemiologic Studies-Depression)Tj
T*
[(Scale and the Geriatric Depression Scale. )54.8 (Arch Intern Med)]TJ
0 Tc 0 Tw T*
(1997;157:449-54.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (Parikh RM, Eden DT)73.9 (, Price )17.7 (TR, Robinson RG. )17.7 (The sensitivity and)]TJ
2.175 -1.25 Td
(specificity of the Center for Epidemiologic Studies Depression)Tj
T*
(Scale in screening for post-stroke depression. Int J Psychiatry Med)Tj
0 Tc 0 Tw T*
(1988;18:169-81.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875.1 (Rhee SH, Petroski GF)79.7 (, Parker JC, et al. )54.8 (A)-220.1 (confirmatory factor)]TJ
2.175 -1.25 Td
(analysis of the Center for Epidemiologic Studies Depression Scale)Tj
T*
(in rheumatoid arthritis patients: additional evidence for a )Tj
T*
[(four)19.7 (-factor model. )54.8 (Arthritis Care Res 1999;12:392-400.)]TJ
-2.175 -1.25 Td
[(33.)-875.1 (Ickovics JR, Hambur)17.7 (ger ME, )17.7 (Vlahov D, et al. Mortality)64.8 (, CD4 cell)]TJ
2.175 -1.25 Td
[(count decline, and depressive symptoms among HIV)91.7 (-seropositive)]TJ
T*
[(women: Longitudinal analysis from the HIV)-257.3 (Epidemiology)]TJ
T*
[(Research Study)64.8 (. JAMA)-220.2 (2001;285:1466-74.)]TJ
-2.175 -1.25 Td
[(34.)-875.1 (Clark CH, Mahoney JS, Clark DJ, Eriksen LH. Screening for)]TJ
2.175 -1.25 Td
(depression in a hepatitis C population: the reliability and validity of)Tj
T*
(the Center for Epidemiologic Studies Depression Scale \(CES-D\). )Tj
0 Tc T*
[(J )54.9 (Adv Nurs 2002;40:361-9.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(35.)-875.1 (Cohen S, )17.7 (W)39.9 (illiamson GM. Perceived stress in a probability sample)]TJ
2.175 -1.25 Td
[(of the United States. In: Spacapan S, Oskamp S, editors. )17.7 (The social)]TJ
T*
(psychology of health. Newberry Park, CA: Sage Publications;)Tj
0 Tc 0 Tw T*
(1987:31-67.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(36.)-875.1 (W)79.9 (are JE, Snow KK, Kosinski M. SF-36 Health Survey: manual and)]TJ
2.175 -1.25 Td
(interpretation guide. Lincoln, RI: QualityMetric Incorporated; 1993.)Tj
-2.175 -1.25 Td
[(37.)-875.1 (Strand )17.7 (V)128.9 (, Gladman D, Isenber)17.7 (g D, Petri M, Smolen J, )17.7 (T)35 (ugwell P)110.7 (.)]TJ
2.175 -1.25 Td
(Outcome measures to be used in clinical trials in systemic lupus)Tj
T*
(erythematosus. J Rheumatol 1999;26:490-7.)Tj
-2.175 -1.25 Td
[(38.)-875.1 (Krupp L, LaRocca N, Muir)19.7 (-Nash J, Steinber)17.7 (g )54.8 (A. )17.7 (The fatigue)]TJ
2.175 -1.25 Td
[(severity scale. )54.8 (Application to patients with multiple sclerosis and)]TJ
T*
[(systemic lupus erythematosus. )54.8 (Arch Neurol 1989;46:1)36.8 (121-3.)]TJ
-2.175 -1.25 Td
[(39.)-875.1 (Jette )54.8 (AM. )17.7 (The Functional Status Index: Reliability and validity of a)]TJ
2.175 -1.25 Td
(self-report functional disability measure. J Rheumatol 1987;14)Tj
0 Tw T*
(Suppl:15-21.)Tj
0.02499 Tw -2.175 -1.25 Td
[(40.)-875.1 (T)35 (urk DC, Rudy )17.7 (TE. )17.7 (T)69.9 (oward an empirically derived taxonomy of)]TJ
2.175 -1.25 Td
(chronic pain patients: integration of psychological assessment data.)Tj
T*
(J Consult Clin Psychol 1988;56:233-8.)Tj
-2.175 -1.25 Td
[(41.)-875.1 (Greco CM, Rudy )17.7 (TE, Manzi S. )54.8 (Adaptation to chronic pain in)]TJ
2.175 -1.25 Td
[(systemic lupus erythematosus: )54.8 (Applicability of the)]TJ
T*
[(Multidimensional Pain Inventory)64.8 (. Pain Med 2003;4:39-50.)]TJ
-2.175 -1.25 Td
[(42.)-875.1 (Joreskog KG, S\232rbom D. LISREL)-238.2 (8: User)-37 (\325)55.1 (s reference guide.)]TJ
2.175 -1.25 Td
(Chicago: Scientific Software International; 1996.)Tj
-2.175 -1.25 Td
[(43.)-875.1 (Hu L, Bentler P)110.7 (. Cutof)17.7 (f criteria for fit indices in covariance )]TJ
2.175 -1.25 Td
(structure analysis: Conventional criteria versus new alternatives.)Tj
T*
(Structural Equation Modeling 1999;6:1-55.)Tj
-2.175 -1.25 Td
[(44.)-875.1 (J\232reskog KG, S\232rbom D. PRELIS 2 user)-37 (\325)55.1 (s reference guide: )54.8 (A)]TJ
2.175 -1.25 Td
(program for multivariate data screening and summarization.)Tj
T*
(Chicago: Scientific Software International; 1996.)Tj
-2.175 -1.25 Td
[(45.)-875.1 (Bruce IN, Mak )17.7 (VC, Hallett DC, Gladman DD, Urowitz MB.)]TJ
2.175 -1.25 Td
(Factors associated with fatigue in patients with systemic lupus)Tj
0 Tc T*
[(erythematosus. )54.9 (Ann Rheum Dis 1999;58:379-81.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(46.)-875.1 (V)59.8 (u)-0.1 ( )17.7 (TV)128.8 (, Escalante )54.8 (A. )54.8 (A)-220.1 (comparison of the quality of life of patients)]TJ
2.175 -1.25 Td
(with systemic lupus erythematosus with and without endstage renal)Tj
T*
(disease. J Rheumatol 1999;26:2595-601.)Tj
-2.175 -1.25 Td
[(47.)-875.1 (W)79.9 (ang C, Mayo NE, Fortin PR. )17.7 (The relationship between health)]TJ
2.175 -1.25 Td
(related quality of life and disease activity and damage in systemic)Tj
T*
(lupus erythematosus. J Rheumatol 2001;28:525-32.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Gr)36.8 (eco, et al: Disease activity in SLE)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(267)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
59 0 obj
<>stream
8;Z\6;3L6!#ikn#j>q4W0p3Y=G.YlA]UA?<[#K^CO@7m=nW!PulkOD%Y4hIRO.W[b
/:-+kMuC&b8a!VP`h[3\]CsXL1*>$dgPrS\:XgY4V>E+fWZDK.@?g2"GTTaE)h;1s
kQ.#dioN.P&VpG3""*1H(4UML:lu-uVOPPWZ:.9@7'QJaJ:V4^-R3@-*5i$5UCqY)
T:I+Q+\,^;a`^r/d=V.6i?lNIo[YO+,2Ibc:"RYNA2\/]h3%Ad;W<=4&+0aJ:Us`q
DfFQf?9'/_]/U0(K=0,%F1*d&l8s8_"9#ROZN5is#t`Dt_,t/gR%2*k.uDc>_W#:O
.fQ8l(J6Umdguk3HWlfV*ekuO[a&FJ'/(N>Wi/'?Rp01hkrFWl
TPe8&n=SlQLO`ibU@0Fmd#kGn_=.qs`,qR,-!`oI?5hOBcI1VrQOL2jH&nMPAiXf\Mhq\6h>&pTP75[M*e-^R4@[Pj;.i;Wa@7t8Zj=Lo:"^+
p>tC9@h)`.>l]K+]"g,)URsE5R)oI4[3Or"%XoKh;&T2F1JAd#Q7ft9R>$J%9aTon
'6;?ERDFXVr2`D''nSk!;->fS^!lsA%$U;8oBai(;:CE7A4\]PLn8m!n)[NLTaWQ3
@,'e]>JJ#'+f?NV!R@H+ZrGCuTC4Wn;.K"/eBu`u]/".JV_nY2A/*=G;DVb]6&=
Zi_nPDgQ!8FA^SC/"AR"CqK7I!n4[)PLR)N^37](s=XkMq5Zsqg+
(V!]]r1^D=[ebqS;5@U^2Cq7]i@S4Y1mF;@9d3f6o<.kpNBRVp5Aj&uaEZ>$i+eVI
0@P]knNm'l!7^F3Mu~>
endstream
endobj
63 0 obj
[/Indexed/DeviceRGB 255 62 0 R]
endobj
62 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
118 0 obj
<>
endobj
89 0 obj
<>
endobj
82 0 obj
<>
endobj
135 0 obj
<>
endobj
167 0 obj
<>
endobj
83 0 obj
<>
endobj
110 0 obj
<>stream
HUiPSY~1=fpEDFjQP@dFaK aI %$ Q@T
QǡjTnkF=/}:LnsW;U8fl8nA Mtps(>w]~/h^kD;jcDž8sMscF?)~2!;_*+? \\w,[+qfCǹnn[]<,^Ro9[wxwwp \NX(9Y~Vxq
9Y\!7+ǐ}?1'sDYT8'\'>#q?3 D^|+O%
\}¶b6°Xm}jF`$R0%UFQb#A5N14\b00=gMg33`6{"tŐ9\yeʻvƭ3l6SSaIKG8,CqYQO^yjŊVi}rUL\Xs@)հYBݠPfd2XE"xkڮl-wdR}rjP oP>2>$X_۞W;Pi;%"LҲoo\WVPӍ.O8~̾\jhNy$23:5$.[*]7Uѻ=z~lEdIu}IVZQ,tBe9Q|"-sUz'V7oq